Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...

March 3 () - Moderna has agreed to pay Genevant Sciences, a ‌subsidiary of Roivant Sciences, and Arbutus ‌Biopharma up to ...

Roivant Sciences snapshot after recent performance Roivant Sciences (ROIV) has drawn fresh attention after a strong share price move, with the stock showing gains over the past month and past 3 months ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Well, good morning, everybody, and thank you once again for joining us for the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's a great pleasure to moderate ...

The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. 10 stocks we like better than Roivant Sciences › Commercial-stage biotech Roivant ...

Priovant Therapeutics, affiliated with Roivant Sciences, recently announced that the U.S. FDA accepted and granted Priority Review to its New Drug Application for brepocitinib in dermatomyositis, with ...

The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

Roivant Sciences ROIV will release its quarterly earnings report on Thursday, 2025-05-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Roivant Sciences to ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...